{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-093942","form_type":"8-K","ticker":"TRVI","cik":"0001563880","company_name":"Trevi Therapeutics, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.533775+00:00","generated_at":"2026-05-31T10:54:25.696668+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Trevi Therapeutics Q2 net loss $12.4M; RIVER trial ~80% enrolled, topline Q4 2024","bullets":["Q2 2024 net loss of $12.4M vs $7.1M in Q2 2023; R&D expenses $10.0M, up from $5.8M.","Cash and equivalents $69.5M; cash runway expected into 2026.","Phase 2a RIVER trial (RCC) ~80% enrolled; topline data expected Q4 2024.","Phase 2b CORAL trial (IPF cough) sample size re-estimation expected Q4 2024; topline H1 2025.","Appointed Margaret Garin, MD, MSCR as VP of Clinical Development."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-093942","json":"https://secwatch.observer/filing/0000950170-24-093942.json","markdown":"https://secwatch.observer/filing/0000950170-24-093942.md","text":"https://secwatch.observer/filing/0000950170-24-093942.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563880/000095017024093942/0000950170-24-093942-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563880/000095017024093942/trvi-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:54:25.696668+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}